Quest Diagnostics Incorporated Stock News

Although the revenue and EPS for Quest Diagnostics (DGX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with

Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.

Quest Diagnostics (DGX) came out with quarterly earnings of $2.15 per share, beating the Zacks Consensus Estimate of $2.14 per share. This compares to earnings of $1.98 per share a year ago.

Quest Diagnostics' (DGX) subsidiary Haystack Oncology collaborates with TriSalus Life Sciences to improve therapeutic options for aggressive forms of cancer.

Stocks such as EXAS, DGX and LH are likely to potentially continue the momentum in the oncology field.

Prestige Consumer Health (PBH), Quest Diagnostics (DGX) and Hologic (HOLX) are currently at discounted zone that are expected to provide long-term gains.

Quest Diagnostics (DGX) partners with Fitbit to study the potential of wearable devices to improve metabolic health.

Blood tests for dozens of types of cancer have been invented. These tests, known as liquid biopsies, could save tens of millions of lives.

SECAUCUS, N.J. , Jan. 17, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that it will report fourth quarte

Quest Diagnostics' (DGX) new partnership is likely to leverage its oncology expertise and national scale.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.

Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.

Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.

Quest Diagnostics' (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey.